PharmaIN and LAT Pharma have announced the issuance of FDA orphan-drug designation for terlipressin as treatment of ascites due to all etiologies apart from cancer. The companies are developing long-acting PHT101(PGC-C12E-Terlipressin)for ...
Tags: PharmaIN-LAT Pharma ascite therapy, FDA orphan-drug designation, PHT101